Jacobs Levy Equity Management Inc. increased its position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 39.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 313,013 shares of the company's stock after purchasing an additional 88,532 shares during the period. Jacobs Levy Equity Management Inc. owned 0.55% of Harmony Biosciences worth $10,771,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in HRMY. JPMorgan Chase & Co. increased its stake in shares of Harmony Biosciences by 68.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 230,428 shares of the company's stock worth $9,217,000 after acquiring an additional 93,622 shares in the last quarter. Swiss National Bank increased its stake in shares of Harmony Biosciences by 28.2% during the fourth quarter. Swiss National Bank now owns 78,200 shares of the company's stock valued at $2,691,000 after purchasing an additional 17,200 shares in the last quarter. Teacher Retirement System of Texas increased its stake in shares of Harmony Biosciences by 50.6% during the fourth quarter. Teacher Retirement System of Texas now owns 11,801 shares of the company's stock valued at $406,000 after purchasing an additional 3,964 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Harmony Biosciences by 36.4% during the fourth quarter. Vanguard Group Inc. now owns 4,733,609 shares of the company's stock valued at $162,883,000 after purchasing an additional 1,262,362 shares during the last quarter. Finally, Barclays PLC boosted its position in shares of Harmony Biosciences by 110.9% in the 3rd quarter. Barclays PLC now owns 76,862 shares of the company's stock worth $3,074,000 after purchasing an additional 40,416 shares in the last quarter. 86.23% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
A number of research firms have weighed in on HRMY. HC Wainwright reissued a "buy" rating and issued a $70.00 target price on shares of Harmony Biosciences in a report on Tuesday, April 8th. UBS Group dropped their target price on shares of Harmony Biosciences from $55.00 to $48.00 and set a "buy" rating for the company in a research report on Monday, April 28th. Needham & Company LLC reiterated a "buy" rating and issued a $49.00 target price on shares of Harmony Biosciences in a research report on Tuesday, May 6th. Deutsche Bank Aktiengesellschaft initiated coverage on Harmony Biosciences in a report on Tuesday, February 11th. They set a "buy" rating and a $55.00 price target for the company. Finally, Mizuho increased their target price on Harmony Biosciences from $44.00 to $48.00 and gave the company an "outperform" rating in a research report on Thursday. Eight equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $52.78.
Check Out Our Latest Analysis on Harmony Biosciences
Harmony Biosciences Stock Up 2.5%
NASDAQ:HRMY traded up $0.84 during trading hours on Friday, reaching $35.07. The company's stock had a trading volume of 410,868 shares, compared to its average volume of 592,644. The stock has a 50 day moving average price of $31.45 and a two-hundred day moving average price of $33.96. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.20 and a current ratio of 3.24. The company has a market capitalization of $2.01 billion, a P/E ratio of 16.62, a price-to-earnings-growth ratio of 0.47 and a beta of 0.82. Harmony Biosciences Holdings, Inc. has a 12 month low of $26.47 and a 12 month high of $41.61.
Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.59 by $0.19. The firm had revenue of $184.73 million during the quarter, compared to analyst estimates of $184.26 million. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. Harmony Biosciences's revenue was up 19.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.67 EPS. Equities analysts predict that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current fiscal year.
Harmony Biosciences Company Profile
(
Free Report)
Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
Further Reading
Before you consider Harmony Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harmony Biosciences wasn't on the list.
While Harmony Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
